Related Experiment Video
Updated: Jul 9, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Ultrafast 30-min infusion of a rituximab biosimilar (Truxima)
Ernesto Pérez-Persona1, Laida Cuevas Palomares2,3, Ariane Unamunzaga Cilaurren2
1Department of Haematology Complejo Hospitalario de Navarra Pamplona Spain.
Abstract:
In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.
More Related Videos
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018